Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 68.23M P/E - EPS this Y 41.90% Ern Qtrly Grth -
Income -26.54M Forward P/E -3.39 EPS next Y 15.30% 50D Avg Chg 41.00%
Sales 10.76M PEG - EPS past 5Y - 200D Avg Chg 173.00%
Dividend N/A Price/Book 4.34 EPS next 5Y - 52W High Chg -39.00%
Recommedations 2.50 Quick Ratio 1.87 Shares Outstanding 32.96M 52W Low Chg 705.00%
Insider Own 8.93% ROA -30.31% Shares Float 16.51M Beta -
Inst Own 48.71% ROE -97.40% Shares Shorted/Prior 274.42K/51.61K Price 2.07
Gross Margin -185.15% Profit Margin -246.71% Avg. Volume 529,309 Target Price 2.50
Oper. Margin -240.64% Earnings Date Nov 14 Volume 152,923 Change 0.00%
LogicBio Therapeutics, Inc. News
11/14/22 LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
10/03/22 AstraZeneca acquires local startup at 660% premium
10/03/22 LogicBio's stock skyrockets after buyout bid for a 667% premium
10/03/22 Why Are LogicBio Therapeutics Shares Skyrocketing Today?
10/03/22 Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine
09/28/22 The Zacks Analyst Blog highlights Consolidated Water, Ashford Hospitality Trust, BankFinancial, LogicBio Therapeutics and ProPhase Labs
09/27/22 5 Big Winners as Dollar Strengthens on Fed Rate Hike
09/21/22 LogicBio® Therapeutics Announces Pre-Clinical Results for mLB-001 Published in Peer-reviewed Journal PLOS ONE
08/18/22 Earnings Update: LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported And Analysts Are Boosting Their Estimates
08/15/22 LogicBio Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
07/27/22 LogicBio Therapeutics (LOGC) Moves to Buy: Rationale Behind the Upgrade
05/17/22 LogicBio® Therapeutics to Present at H.C. Wainwright Global Investment Conference
05/16/22 LogicBio Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Business Updates
05/11/22 LogicBio Therapeutics Announces Upcoming Presentations on GeneRide Development Candidate and Multiple Advancements in AAV Manufacturing Processes at ASGCT Annual Meeting
05/09/22 LogicBio Therapeutics Shares Skyrocket As FDA Lifts Clinical Hold On Its Pediatric Trial
05/09/22 LogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic Acidemia
03/23/22 LogicBio Therapeutics to Present at H.C. Wainwright Gene Therapy and Gene Editing Conference
03/08/22 LogicBio Therapeutics to Present at Barclays Global Healthcare Conference
04:05 PM LogicBio Therapeutics Reports Full Year 2021 Financial Results and Provides Business Updates

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. As of November 15, 2022, LogicBio Therapeutics, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc..

LOGC Chatroom

User Image skyrockets_Inc Posted - 1 day ago

$VLON 3 day 15min - charts. Bottom is $VLON and top is $LOGC the last 3 days before it got bought out for $2. Eerily similiar??? LFG!!!

User Image cctranscripts Posted - 11/29/22

Securities registration termination [Section 12(g)] https://www.conferencecalltranscripts.org/summary/?id=11564094 $LOGC

User Image Quantisnow Posted - 11/29/22

$LOGC 📜 SEC Form 15-12G filed by LogicBio Therapeutics Inc. https://quantisnow.com/i/3745780?utm_source=stocktwits 45 seconds delayed.

User Image fla Posted - 11/29/22

$LOGC [15s. delayed] filed form 15-12G on November 29, 16:06:16 https://s.flashalert.me/WJCMrT

User Image risenhoover Posted - 11/29/22

$LOGC / LogicBio Therapeutics files form 15-12G https://fintel.io/sf/us/logc?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing

User Image Newsfilter Posted - 11/29/22

$LOGC Form 15-12G (securities registration termination [section 12(g)]) filed with the SEC https://newsfilter.io/a/750e3aaab9064327f57b70e33f7461f1

User Image macroaxis Posted - 11/29/22

$LOGC - Is there a new start for Logicbio Therapeutics? May slip from Delisting on the 17th of… #stocks #earnings

User Image efeninoglu Posted - 11/22/22

$LOGC sprong from 0.25 to 2 was that split 1/10 ?

User Image cctranscripts Posted - 11/21/22

Notice of Effectiveness https://www.conferencecalltranscripts.org/summary/?id=11531978 $LOGC

User Image Quantisnow Posted - 11/21/22

$LOGC 📜 SEC Form EFFECT filed by LogicBio Therapeutics Inc. https://quantisnow.com/i/3711866?utm_source=stocktwits 45 seconds delayed.

User Image fla Posted - 11/21/22

$LOGC [15s. delayed] filed form EFFECT on November 21, 00:15:18 https://s.flashalert.me/gS3o5g

User Image Newsfilter Posted - 11/21/22

$LOGC Form EFFECT (notice of effectiveness) filed with the SEC https://newsfilter.io/a/685cbbec522ef40e37f8975e01f47527

User Image shortablestocks Posted - 11/18/22

Zero shares available to short currently in $LOGC. https://shortablestocks.com/?LOGC

User Image fla Posted - 11/17/22

$LOGC [15s. delayed] filed SEC form 4: Director Kay Mark A: Disposed 784,557 of Common Stock on 2022-11-16, decreased holding by 100% to https://s.flashalert.me/YnZ1s

User Image Newsfilter Posted - 11/17/22

$LOGC Form 4 (statement of changes in beneficial ownership of securities) filed with the SEC https://newsfilter.io/a/8e8974c289a077ab01fc6067a71a90c1

User Image Newsfilter Posted - 11/17/22

$LOGC reported 5 new insider trades to the SEC in the last 2 minutes. 100,000 shares sold by Nacht Mariana (Chief Scientific Officer) https://newsfilter.io/articles/4-form-88a68e32dd78bdf5880cef7f11bf5691 3,141 shares sold by Wyzga Michael S (Director) https://newsfilter.io/articles/4-form-7981bbc9210502161dcb80a68aa444aa 253,811 shares sold by Chereau Frederic (President, CEO) https://newsfilter.io/articles/4-form-ba9d183f53d15483e32de1f7a4ebd3a0 12,500 shares sold by Goater Jeff (Director) https://newsfilter.io/articles/4-form-44bfd3b190f65301fa687c11898e89fc 2,921 shares sold by Enyedy Mark J (Director) https://newsfilter.io/articles/4-form-149f6af9d97c37f2a8690ec4c7b6fe4b

User Image fla Posted - 11/17/22

$LOGC [15s. delayed] filed SEC form 4: Director Enyedy Mark J: Disposed 2,921 of Common Stock on 2022-11-16, decreased holding by 100% to https://s.flashalert.me/0kFGK

User Image fla Posted - 11/17/22

$LOGC [15s. delayed] filed SEC form 4: Chief Scientific Officer Nacht Mariana: Transacted Derivative Securities on 2022-11-16. https://s.flashalert.me/VjfBt

User Image fla Posted - 11/17/22

$LOGC [15s. delayed] filed SEC form 4: Director WYZGA MICHAEL S: Disposed 3,141 of Common Stock on 2022-11-16, decreased holding by 100% https://s.flashalert.me/5OPDLr

User Image fla Posted - 11/17/22

$LOGC [15s. delayed] filed SEC form 4: President, CEO Chereau Frederic: Disposed 253,811 of Common Stock on 2022-11-16, decreased holding https://s.flashalert.me/dDnYt

User Image fla Posted - 11/17/22

$LOGC [15s. delayed] filed SEC form 4: Director Goater Jeff: Transacted Derivative Securities on 2022-11-16. https://s.flashalert.me/B8Xgp

User Image fla Posted - 11/17/22

$LOGC [15s. delayed] filed SEC form 4: Director MOSCICKI RICHARD A: Disposed 3,916 of Common Stock on 2022-11-16, decreased holding by 10 https://s.flashalert.me/O1SFw

User Image Newsfilter Posted - 11/17/22

$LOGC Form 4 (statement of changes in beneficial ownership of securities) filed with the SEC https://newsfilter.io/a/dc5c1e15ee94a8ef2dc2289448e982e2

User Image fla Posted - 11/17/22

$LOGC [15s. delayed] filed SEC form 4: Director Karydas Daphne: Transacted Derivative Securities on 2022-11-16. https://s.flashalert.me/iMeFV

User Image Newsfilter Posted - 11/17/22

$LOGC reported 3 new insider trades to the SEC in the last 2 minutes. 22,333 shares sold by Chen Leon (Director) https://newsfilter.io/articles/4-form-0493acb75e455ac36d1869c6a0403f2a 3,331 shares sold by Gruskin Daniel (Chief Medical Officer) https://newsfilter.io/articles/4-form-7380a849b7eddf1149a269b06d319ff2 12,500 shares sold by Karydas Daphne (Director) https://newsfilter.io/articles/4-form-e9bfede430326b5e8738864c043d05f3

User Image fla Posted - 11/17/22

$LOGC [15s. delayed] filed SEC form 4: Director Chen Leon: Disposed 22,333 of Common Stock on 2022-11-16, decreased holding by 100% to 0 https://s.flashalert.me/mp0oyS

User Image cctranscripts Posted - 11/17/22

LogicBio Therapeutics's Chief Medical Officer just disposed of 3,331 shares https://www.conferencecalltranscripts.org/summary/?id=11526207 $LOGC

User Image fla Posted - 11/17/22

$LOGC [15s. delayed] filed SEC form 4: Chief Medical Officer Gruskin Daniel: Disposed 3,331 of Common Stock on 2022-11-16, decreased hold https://s.flashalert.me/dkGZ8

User Image cctranscripts Posted - 11/17/22

LogicBio Therapeutics director just declared 0 options https://www.conferencecalltranscripts.org/summary/?id=11526202 $LOGC

User Image fla Posted - 11/17/22

$LOGC [15s. delayed] filed SEC form 4: Director Kahn Susan: Transacted Derivative Securities on 2022-11-16. https://s.flashalert.me/aCZKR

Analyst Ratings
Chardan Capital Buy Aug 22, 22
Chardan Capital Buy May 17, 22
JMP Securities Market Outperform May 10, 22
William Blair Market Perform Feb 3, 22
Chardan Capital Hold Feb 2, 22
Chardan Capital Buy Dec 23, 21
Barclays Overweight Nov 17, 21
JMP Securities Market Outperform Nov 16, 21
HC Wainwright & Co. Buy Jun 7, 21